CMND ▲ +5.1% - Clearmind Medicine Inc. $CMND - Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial Clearmind Medicine shares rose 5.1% following the company's announcement that it has enrolled the first patients in its CMND-100 clinical trial for alcohol use disorder. The initiation of patient enrollment in a clinical program is typically viewed as a de-risking milestone that advances the company's pipeline toward potential regulatory approval and commercialization. 11-SEP-2026 08:01 AM ET